MetaCap

uniQure N.V. (QURE) vs Tyra Biosciences (TYRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tyra Biosciences (TYRA) has outperformed uniQure N.V. (QURE) over the past year, losing 4.7% versus a loss of 30.4%. Over five years, TYRA leads with a -15.7% price change compared with -32.9% for QURE. Tyra Biosciences is the larger company by market cap ($1.39 billion vs $1.36 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

QURE-30.42%TYRA-4.73%
+95%+10%-75%
Nov 21, 20251 yearNov 20, 2026
QURE-34.72%TYRA-16.17%
+139%+21%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

QURE versus TYRA key metrics
MetricQURETYRA
Share price$19.35$20.12
Market cap$1.36B$1.39B
1-day change-4.35%+1.98%
YTD return-19.14%-23.47%
1-year return-30.42%-4.73%
5-year return-32.86%-15.71%
EPS (TTM)$-3.51$-2.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$16.10M—
Revenue growth (YoY)-40.64%—
Net income (latest FY)$-198.97M$-119.95M
Gross margin89.53%—
Operating margin-1151.38%—
Net margin-1236.00%—
52-week high$51.72$40.65
52-week low$8.73$18.25
Distance from 52-week high-62.59%-50.50%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+207.03%+135.83%
Average volume2.26M852.56K
Shares outstanding70.14M69.08M
Employees22187
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TYRA has outperformed QURE by 25.7 percentage points over the past year.

About uniQure N.V.

QURE stock →

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees

About Tyra Biosciences

TYRA stock →

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

QURE vs TYRA FAQ

Which is bigger, uniQure N.V. or Tyra Biosciences?

Tyra Biosciences (TYRA) is larger, with a market capitalization of $1.39B compared with $1.36B for uniQure N.V. (QURE).

Which stock has performed better over the past year, QURE or TYRA?

TYRA returned -4.73% over the past 12 months, compared with -30.42% for QURE (price return, excluding dividends). Past performance does not predict future results.

Are uniQure N.V. and Tyra Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons